secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENXBIO Inc. (RGNX)
CIK:        0001590877
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0000950170-23-017184
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

REGENXBIO Q1 net loss $66.7M ($1.53/share); cash $473.5M; pipeline advances
---------------------------------------------------------------------------

- Cash, equivalents and marketable securities $473.5M as of Mar 31, 2023; runway into 2025.
- Revenue $19.1M, down from $22.2M YoY mainly due to lower Zolgensma royalties ($16.1M vs $21.5M).
- Net loss $66.7M ($1.53 per share) vs $76.7M ($1.79) YoY; R&D spend up to $58.5M.
- Subretinal ABBV-RGX-314 pivotal trials expanded; regulatory submissions expected late 2025 to H1 2026.
- RGX-202 Duchenne trial on track for initial data H2 2023; RGX-121 BLA filing planned in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590877/000095017023017184/0000950170-23-017184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590877/000095017023017184/rgnx-20230503.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-017184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer